INOVIO Pharmaceuticals, Inc. (INO) announced Monday that it plans the first dose of its COVID-19 vaccine today as it initiates Phase 1 clinical efficacy trial of INO-4800, its DNA vaccine candidate, in healthy volunteers.
from RTT - Biotech https://ift.tt/2UN7B8K
via IFTTT
No comments:
Post a Comment